Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-BCMA CAR mRNA tLNP
- Development stage
- Preclinical
- Lead developer
- Aera Therapeutics
- Modality
- Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
anti-BCMA CAR mRNA tLNP is an in vivo CAR-T cell therapy candidate developed by Aera Therapeutics for the treatment of plasma cell malignancies, such as multiple myeloma. The therapy utilizes a proprietary targeted lipid nanoparticle (tLNP) platform to deliver mRNA encoding a chimeric antigen receptor (CAR) specific for B-cell maturation antigen (BCMA) directly to CD8+ T cells within the patient's body. This approach aims to eliminate the need for ex vivo cell manipulation, expansion, or lymphodepleting conditioning, which are standard for traditional CAR-T therapies. Preclinical studies in humanized mice and non-human primates have demonstrated that the tLNP effectively delivers the CAR mRNA to resting T cells, resulting in dose-dependent tumor control and depletion of plasma cells in the peripheral blood and bone marrow.
- Other names
- in vivo anti-BCMA CAR-T
02
Targets
CD8A (CD8 alpha/beta Coreceptor)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on anti-BCMA CAR mRNA tLNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-BCMA CAR mRNA tLNP.